Last reviewed · How we verify
Tislelizumab + radiotherapy
Tislelizumab is a PD-1 inhibitor that blocks the interaction between PD-1 on T cells and PD-L1/PD-L2 on tumor cells, restoring anti-tumor immune responses, and is combined with radiotherapy to enhance local and systemic tumor control.
Tislelizumab is a PD-1 inhibitor that blocks the interaction between PD-1 on T cells and PD-L1/PD-L2 on tumor cells, restoring anti-tumor immune responses, and is combined with radiotherapy to enhance local and systemic tumor control. Used for Non-small cell lung cancer (in combination with radiotherapy), Other solid tumors amenable to radiotherapy (investigational).
At a glance
| Generic name | Tislelizumab + radiotherapy |
|---|---|
| Sponsor | First Affiliated Hospital Xi'an Jiaotong University |
| Drug class | PD-1 inhibitor |
| Target | PD-1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
Tislelizumab binds to programmed death receptor-1 (PD-1) on T lymphocytes, preventing engagement with its ligands (PD-L1 and PD-L2) expressed on tumor and immune cells, thereby releasing the brake on anti-tumor immunity. When combined with radiotherapy, the immunotherapy synergizes with radiation-induced tumor cell death and immunogenic effects to amplify T-cell activation and improve overall anti-tumor efficacy.
Approved indications
- Non-small cell lung cancer (in combination with radiotherapy)
- Other solid tumors amenable to radiotherapy (investigational)
Common side effects
- Immune-related pneumonitis
- Immune-related hepatitis
- Immune-related colitis
- Fatigue
- Radiation dermatitis (enhanced by combination)
Key clinical trials
- Brentuximab Vedotin for Newly Diagnosed cHL in Chinese CAYA Based on PET/CT Assessment (PHASE2, PHASE3)
- Short-Course RT Plus CAPOX and Tislelizumab vs Long-Course CRT Plus Tislelizumab for Locally Advanced Rectal Cancer (PHASE2)
- PULSAR Combined With Fecal Microbiota Transplantation for Advanced Hepatocellular Carcinoma Progressing After First-Line Targeted-Immunotherapy (PHASE2)
- Neoadjuvant Chemotherapy and PD-1 Inhibitor for Locally Advanced Rectal Cancer（CONTROL-01） (PHASE2)
- Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer (PHASE1)
- Efficacy and Safety of Tislelizumab Combined With Gemcitabine and Peraspartase in the Treatment of Patients With Primary Stage I-II NK/T Cell Lymphoma
- Study of Tislelizumab Combined With Chemoradiotherapy and Surgery for Unresectable Esophageal Squamous Cell Carcinoma (PHASE2)
- Tislelizumab Combined With Chemotherapy Followed by Thoracic Consolidation Radiotherapy in the First-line Treatment of Extensive Stage Small Cell Lung Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: